DCC-3116, an orally active ULK1/2 inhibitor, has been shown to inhibit KRAS G12C signaling and promote autophagy in lung cancer cells. By doing so, it suppresses the proliferation of lung cancer cells, thereby exerting anticancer effects [1].

DCC-3116 (100 nM, 72 h) alone inhibits the proliferation of NCI-H2122 and Calu-1 cells and reduces the expression of pS318-ATG13. It demonstrates a synergistic effect when used in combination with Sotorasib [1].

DCC-3116, administered alone or in combination with Sotorasib, effectively suppresses tumor growth in mouse models of NSCLC lung cancer. The compound was given daily at a dosage of either 3 or 30 mg/kg for 56 days, utilizing both p.o. and p.i. methods. The study involved adult mice, initiated at 6-8 weeks of age, and resulted in inhibited tumor growth and improved survival rates, although it notably reduced body weight by more than 20%.